Review article: linaclotide for the management of irritable bowel syndrome with constipation

BACKGROUND: Irritable bowel syndrome with constipation (IBS-C) represents a significant burden to patients and healthcare systems due to its prevalence and lack of successful symptomatic resolution with established treatment options. Linaclotide 290 μg has recently been approved by the European Medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Layer, P, Stanghellini, V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305214/
https://www.ncbi.nlm.nih.gov/pubmed/24433216
http://dx.doi.org/10.1111/apt.12604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305214/
https://www.ncbi.nlm.nih.gov/pubmed/24433216
http://dx.doi.org/10.1111/apt.12604

Ejemplares similares